期刊文献+

白藜芦醇乳脂体小鼠体内药动学及组织分布研究 被引量:1

Pharmacokinetics and Tissue Distribution of Resveratrol Emulsome in Mice
下载PDF
导出
摘要 目的研究白藜芦醇乳脂体在小鼠体内的药动学与组织分布。方法采用薄膜分散法制备白藜芦醇乳脂体。以白藜芦醇乳剂为对照,考察乳脂体小鼠尾静脉注射后的药动学及组织分布。采用3P97程序计算药动学参数,并计算Re、Te。结果乳脂体在小鼠体内过程符合二室模型,主要药动学参数:T1/2β为50.17min;AUC为67.29μg.min.mL-1。乳脂体在心、肝、脾、肺、肾的Re分别为2.10、2.16、1.80、1.42、1.34。Te分别为0.92、1.60、0.94、0.79、0.25,Ce分别为1.31、1.18、0.70、0.29、0.43,乳脂体在各组织的分布特点:C肝>C心>C脾>C肺>C肾。结论乳脂体能相对延长白藜芦醇在体内滞留时间,且明显改变了小鼠体内的分布。 OBJECTIVE To study the pharmacokinetics and tissue distribution of Resveratrol emulsome in mice. METHODS Resvertrol emulsome was prepared by thin film dispersion (TFD). Resvertrol emulsome injection pharmacokinetic parame ters and tissue distribution had been modeled with 3p97 program and statistic rules comparing with resvertrol emulsion. RE- SULTS The concentration-time curve of emulsome and emulsion after iv were in accordance with a two-compartment model and the main pharmaeokinetic parameters were as follows: T1/2β50.17 rain, AUC 67.29μg. min-mL 1 . Relative exposure (Re) of emulsome in heart, liver, spleen, lung, kidney was 2.10, 2.16, 1.80, 1.42, 1.34. Targeting efficiency was 0.92, 1.60, 0.94, 0.79, 0.25 and the ratio of maximum concentration was 1.31, 1.18, o. 70, o. 29, o. 43. The tissue distribution feature of emulsome was Cliver〉Cheart〉Cspleen〉Clung〉Ckldney. CONCLUSION The results indicate that emulsome injection could extend the retention time of resveratrol and improve drug concentration in mice with resveratrol emulsion.
出处 《南京中医药大学学报》 CAS CSCD 北大核心 2012年第4期350-353,共4页 Journal of Nanjing University of Traditional Chinese Medicine
基金 河南省科技厅科技发展项目(0524420044)
关键词 白藜芦醇 乳脂体 药代动力学 组织分布 高效液相色谱法 Resveratrol emulsome pharmacokinetic tissue diatribution HPLC
  • 相关文献

参考文献7

  • 1Das DK, Sato M, Ray PS, et al. Cardioprotection of red wine: role of polypheohc antioxidants[J]. Drugs Exp Clin Res, 1999, 25(2/3) ;115.
  • 2康彦芳,封军来,杜鹏,陈炜,杨华.白藜芦醇药理作用及其制备方法[J].粮食与油脂,2006,19(11):37-39. 被引量:10
  • 3Das S, Das DK. Resveratrol: a therapeutic promise for cardio- vascular diseases[J]. Recent Patents Cardiwase Drug Discuv, 2007,2(2) : 133-138.
  • 4Araki T, Sasaki Y, Milbrandt J, et al. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration [J]. Sci,2004,305(5686) : 1010-1013.
  • 5Swati Gupta, Suresh PVyas. Development and characterization of amphoteriein B hearing emulsomes for passive and active mac- rophage targeting[J]. J Drug Targ,2007,15(3) :206-217.
  • 6Vyas SP, Subhedar R, Jain S. Development and characterization of emulsomes for sustained and targeting delivery of an antiviral agent to liver[J]. J Pharm Pharmacol,2006,58(3): 321-326.
  • 7Hoetelmans RM, Pt M, Mennhorst PL,et al. Quantitative de- termination of(-) -2 ' -deoxy-3 ' thiacytidine in human plasma, salivaand cerehmspinal fluid by higU-performance liquid chroma- tography with ultraviolet detection[J]. Chromatogr B Biomed Sci Appl,1998,713(2) :387.

二级参考文献20

共引文献9

同被引文献10

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部